The treatment of insulin dependent diabetes mellitus. May be used for diabetics requiring a depot insulin of medium duration. Where a more rapid, intense onset is desirable it may be mixed with Hypurin® Porcine Neutral.
The treatment of insulin dependent diabetes mellitus. May be used for diabetics who require an insulin of prompt onset and short duration. It is a suitable preparation for admixture with longer acting insulins. It is particularly useful where intermittent, short term or emergency therapy is required, during initial stabilisation and in the treatment of labile diabetes.
The treatment of insulin dependent diabetes mellitus. May be used for diabetics requiring a depot insulin of medium duration. Where a more rapid, intense onset is desirable it may be mixed with Hypurin Neutral.
The treatment of insulin dependent diabetes mellitus. May be used for diabetics requiring a depot insulin of intermediate duration.
The FDA on 9 March 2012 approved Gintuit from Organogenesis Inc., being the first cell-based product made from allogeneic human...
Edwards Lifesciences Corporation announced the company's EVOQUE tricuspid valve replacement system received CE Mark for the transcatheter treatment of eligible patients with tricuspid regurgitation (TR) . The EVOQUE system is the world's first transcatheter valve replacement therapy to receive regulatory approval to treat TR.
The medicinal product is to be used for disinfection of the skin prior to invasive medical procedures.